Ajanta Pharma Limited

AJANTPHARM NSE Healthcare Pharmaceuticals
Nifty 500 Midcap 150 LargeMid 250
₹3,533.40
+0.38%
Delayed · cached 15 min
Fair Value Analysis →

Price Chart

Price50-day avg200-day avg

How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.

Strengths

  • Low debt: debt-to-equity of 0.06.
  • Comfortable interest cover: operating profit covers interest about 93.8 times.
  • Return on equity is healthy at 27.1%.
  • Return on capital employed is healthy at 34.5%.
  • Net profit margin is strong at 19.4%.
  • Profit has compounded about 12% a year over five years.
  • Sales have compounded about 14% a year over five years.
  • Pays a dividend (yield about 0.91%).
  • Has paid a dividend in each of the last 5 years on record.
  • Promoters hold a majority stake (63.49%).

!Watch-points

No notable watch-points flagged by the automated checks.

These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.

Forensic Checks

Altman Z-ScoreSafe zone
7.16

In Altman’s original study, companies in this range showed a low incidence of financial distress.

Computed without the working-capital term (current-asset split not available for this stock).

Piotroski F-ScoreWeak
3 / 7

The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.

Based on 7 of the 9 signals — the rest need data not available for this stock.

These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.

Key Ratios

Market Cap₹ 44,153 Cr
Current Price₹ 3,533.40
High / Low₹ 3,796.00 / 2,329.90
Stock P/E38.909813
Book Value₹ 362.00
Dividend Yield0.8%
ROCE34.50%
ROE27.10%
Face Value₹ 2.00
Debt to Equity0.06
PEG Ratio1.62
EV / EBITDA26.55
Industry PE35.70
P/B Ratio9.751237
EPS₹ 84.52
Debt₹ 260 Cr
PAT Margin19.37%
Cash PAT₹ 1,229 Cr
ICR93.75
Promoter Holding63.49%
FII Holding7.68%
DII Holding21.80%
Public Holding7.03%

Note on calculated ratios: where a value is not published in the source data, we compute it from the reported financials — Debt to Equity = total borrowings ÷ (equity capital + reserves); EV / EBITDA = (market cap + debt − cash) ÷ (operating profit + depreciation); PEG = P/E ÷ 3-year profit growth %. These may differ slightly from other sources that use different periods or TTM figures. Current Price, Market Cap and P/E reflect the live quote (cached 15 min).

Compounded Sales Growth
10 Years 12.00%
5 Years 14.00%
3 Years 13.00%
TTM 20.00%
Compounded Profit Growth
10 Years 10.00%
5 Years 12.00%
3 Years 24.00%
TTM 22.00%
Stock Price CAGR
10 Years 11.00%
5 Years 20.00%
3 Years 25.00%
1 Year 37.00%
Return on Equity
10 Years 23.00%
5 Years 23.00%
3 Years 25.00%
Last Year 27.00%
Educational data only. Not a recommendation to buy, sell or hold any security.